World News | 64 Foreign Envoys Leave for Hyderabad to Visit Biotech Companies Developing COVID-19 Vaccine

Get latest articles and stories on World at LatestLY. 64 foreign envoys, who are scheduled to visit leading biotech companies - Bharat Biotech and Biological E - which are developing vaccines against the novel coronavirus, have left for Hyderabad.

New Delhi [India], December 9 (ANI): 64 foreign envoys, who are scheduled to visit leading biotech companies - Bharat Biotech and Biological E - which are developing vaccines against the novel coronavirus, have left for Hyderabad.

Sources said that this is the first such visit and it will be followed by visits to facilities in other cities.

Also Read | 2 Terrorists Killed in Encounter With Security Forces at Tiken Area of Pulwama: Live Breaking News Headlines & Coronavirus Updates, December 9, 2020.

It is in continuation of the COVID-19 briefing by the Ministry of External Affairs on November 6.

India is the world's largest vaccine manufacturer and has been contributing significantly to global efforts against COVID-19 pandemic.

Also Read | Donald Trump Signs Decree to Grant Americans Priority Access to COVID-19 Vaccines After Questions Raised on Supply.

Sources said there is a lot of interest in India's vaccine development efforts.

Prime Minister Narendra Modi has said that India's vaccine production and delivery capacity will be used to help all humanity in fighting this crisis.

He visited the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India in Pune on November 28 to conduct an extensive review of the vaccine development and manufacturing process.

On November 30, he had virtual meetings with teams from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad. The three teams are working on developing and manufacturing vaccine for COVID-19.

Bharat Biotech had on Monday applied for emergency use authorisation for its indigenously developed COVID-19 vaccine 'Covaxin' to Drugs Controller General of India (DCGI).

It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for the vaccine developed by Oxford University and AstraZeneca. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)

Share Now

Share Now